That is, the immunophenotype for CHL-type PTLD is CD15+, CD20−, CD30+, CD45− and PAX5 weak+, whereas the immunophenotype for polymorphic PTLD with HRS-like cells is usually CD15−, CD20+ and CD45+. Here, PTPRC is linked to post-transplant lymphoproliferative disease.